Evidence map›Paper›PMID 41031883›Full record

ReviewThe Journal of clinical investigation2025

Gut complement system: a new frontier in microbiota-host communication and intestinal homeostasis.

Xianbin Tian, Lan Zhang, Xinyang Qian, Yangqing Peng, Fengyixin Chen, Sarah Bengtson, Zhiqing Wang, Meng Wu

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xianbin TianDepartment of Molecular Microbiology and.
Lan ZhangDepartment of Molecular Microbiology and.
Xinyang QianDepartment of Molecular Microbiology and.
Yangqing PengDepartment of Molecular Microbiology and.
Fengyixin ChenDepartment of Molecular Microbiology and.
Sarah BengtsonDepartment of Molecular Microbiology and.
Zhiqing WangDepartment of Molecular Microbiology and.
Meng WuDepartment of Molecular Microbiology and.

Funding

Exploiting the microbiota-stromal cell axis for microbiota-targeted medicineDP2AI184835 · NIAID · WASHINGTON UNIVERSITY · PI Meng Wu · 2024 to 2026
$1.4M
NIAID NIH HHS DP2 AI184835
6 · The paper itself

Abstract

The gut microbiota plays a crucial role in maintaining intestinal homeostasis and influencing various aspects of host physiology, including immune function. Recent advances have highlighted the emerging importance of the complement system, particularly the C3 protein, as a key player in microbiota-host interactions. Traditionally known for its role in innate immunity, the complement system is now recognized for its interactions with microbial communities within the gut, where it promotes immune tolerance and protects against enteric infections. This Review explores the gut complement system as a possibly novel frontier in microbiota-host communication and examines its role in shaping microbial diversity, modulating inflammatory responses, and contributing to intestinal health. We discuss the dynamic interplay between microbiota-derived signals and complement activation, with a focus on the C3 protein and its effect on both the gut microbiome and host immune responses. Furthermore, we highlight the therapeutic potential of targeting complement pathways to restore microbial balance and treat diseases such as inflammatory bowel disease and colorectal cancer. By elucidating the functions of the gut complement system, we offer insights into its potential as a target for microbiota-based interventions aimed at restoring intestinal homeostasis and preventing disease.

Indexed as

Complement C3Complement System ProteinsGastrointestinal MicrobiomeHomeostasisIntestinesAnimalsColorectal NeoplasmsComplement ActivationHumansImmunity, InnateInflammatory Bowel DiseasesComplement C3Complement System Proteins

Identifiers

PMID41031883
PMCPMC12483559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.